Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mallinckrodt deutschland gmbh - gadoversetamide - immaġni tar-reżonanza manjetika - midja ta 'kuntrast - dan il-prodott mediċinali huwa għal użu dijanjostiku biss. optimark hu indikat għall-użu mal-immaġni tar-reżonanza manjetika (mri) tas-sistema nervuża ċentrali (cns) u l-fwied. jipprovdi titjib tal-kuntrast u jiffaċilita l-viżwalizzazzjoni u jgħin fil-karatterizzazzjoni tal-leżjonijiet fokali u strutturi anormali fis-cns u fil-fwied f'pazjenti b'magħrufa jew issuspettata patoloġija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - linaclotide - sindromu tal-musrana irritabbli - drogi għal stitikezza - constella hija indikata għat-trattament sintomatiku ta 'sindromu tal-musrana irritabbli moderata għal severa b'stitikazzjoni (ibs-c) f'adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaċċini ta 'l-influwenza - profilassi tal-influwenza kkawżata mill-virus a (h1n1v) 2009. focetria għandu jintuża skont il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

baxalta innovations gmbh - susoctocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament ta 'episodji ta' fsada f'pazjenti b'emofilja akkwiżita kkawżata minn antikorpi għall-fattur viii. obizur huwa indikat fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigens tal-wiċċ tal-virus tal-influwenza (emagglutinin u neuraminidase) ta 'razza a / vjet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaċċini - immunizzazzjoni attiva kontra s-sottotip h5n1 tal-virus influwenza a.. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

octapharma ab - simoctocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). vihuma jistgħu jiġu użati għall-gruppi kollha tal-età.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - mard tal-pulmun, obstructive kronika - formoterol u glycopyrronium bromide - bevespi aerosphere huwa indikat bħala l-manutenzjoni bronkodilatur-kura biex ittaffi s-sintomi fil-pazjenti adulti bil-marda pulmonari ostruttiva kronika (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patiromer sorbitex calcium - iperkalemija - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - veltassa huwa indikat għall-kura ta 'iperkalimja fl-adulti.